• 1
    Paley PJ, Swisher EM, Garcia RL, et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oopherectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001;80: 176180.
  • 2
    Rose PG, Shrigley R, Wiesner GL. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. Gynecol Oncol 2000;77(2):319320(May).
  • 3
    Zweemer RP, Van Diest PJ, Verheijen RH, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA 1 germ line mutations. Gynecol Oncol 2000;76(1):4550(January).
  • 4
    Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumours in women with BRCA1 or BRCA2 mutations undergoing prophylactic oopherectomy. J Clin Oncol 2000;18(14):27282732.
  • 5
    Hartley A, Rollason T, Spooner D. Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier prophylactic surgery. Clin Oncol (R Coll Radiol) 2000;12(1):5859.
  • 6
    Sobol H, Jacquemier J, Bonaiti C, et al. Fallopian tube cancer as a feature of BRCA 1 associated syndromes. Gynecol Oncol 2000;78: 263266.
  • 7
    Cancer Genetics Studies ConsortiumRecommendation for follow up care of individuals with an inherited predisposition to cancer. II: BRCA 1 and BRCA 2. JAMA 1997;277(12):9971003(March 26).
  • 8
    Jacobs I, Oram D. Screening for ovarian cancer. Biomed Pharmacother 1998;42: 589596.
  • 9
    Schraget al. Decision analysis—effects of prophylactic mastectomy and oopherectomy on live expectancy among women with BRCA 1 or BRCA 2 mutations. N Engl J Med 1997;336(20):14651471(May 15).